Reports Strong First-Quarter Financial Results NASDAQ:ONTX, NASDAQ:CBMB, NASDAQ:INM, NASDAQ:BOMN

ONCONOVA THERAPEUTICS (NASDAQ:ONTX) EARNINGS INFORMATION (NASDAQ:ONTX)

Onconova Therapeutics last posted its quarterly earnings results on August 12th, 2021. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.01. Onconova Therapeutics has generated ($2.10) earnings per share over the last year (($1.80) diluted earnings per share). Earnings for Onconova Therapeutics are expected to grow in the coming year, from ($1.17) to ($1.14) per share. Onconova Therapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, November 11th, 2021 based off prior year’s report dates.

IS ONCONOVA THERAPEUTICS A BUY RIGHT NOW? (NASDAQ:ONTX)

5 Wall Street research analysts have issued “buy,” “hold,” and “sell” ratings for Onconova Therapeutics in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should “hold” Onconova Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ONTX, but not buy additional shares or sell existing shares.
Onconova Therapeutics

CBM BANCORP (NASDAQ:CBMB) EARNINGS INFORMATION (NASDAQ:CBMB)

CBM Bancorp last posted its quarterly earnings data on May 13th, 2021. The reported $0.04 EPS for the quarter. The company earned $2.01 million during the quarter. CBM Bancorp has generated $0.00 earnings per share over the last year.

WHAT STOCKS DOES MARKETBEAT LIKE BETTER THAN CBM BANCORP? (NASDAQ:CBMB)

Wall Street analysts have given CBM Bancorp a “N/A” rating, but there may be better buying opportunities in the stock market. Some of MarketBeat’s past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but CBM Bancorp wasn’t one of them. MarketBeat thinks these five companies may be even better buys.

INMED PHARMACEUTICALS (NASDAQ:INM) EARNINGS INFORMATION (NASDAQ:INM)

InMed Pharmaceuticals last announced its quarterly earnings results on May 13th, 2021. The reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.24) by $0.17. InMed Pharmaceuticals has generated $0.00 earnings per share over the last year. Earnings for InMed Pharmaceuticals are expected to grow in the coming year, from ($1.44) to ($1.00) per share.

IS INMED PHARMACEUTICALS A BUY RIGHT NOW? (NASDAQ:INM)

1 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for InMed Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should “buy” InMed Pharmaceuticals stock.
InMed Pharmaceuticals

BOSTON OMAHA (NASDAQ:BOMN) EARNINGS INFORMATION (NASDAQ:BOMN)

Boston Omaha last posted its earnings results on May 24th, 2021. The reported $3.09 earnings per share for the quarter. The firm had revenue of $13.21 million for the quarter. Boston Omaha has generated $0.00 earnings per share over the last year ($4.09 diluted earnings per share) and currently has a price-to-earnings ratio of 7.3.

WHAT STOCKS DOES MARKETBEAT LIKE BETTER THAN BOSTON OMAHA? (NASDAQ:BOMN)

Wall Street analysts have given Boston Omaha a “N/A” rating, but there may be better buying opportunities in the stock market. Some of MarketBeat’s past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Boston Omaha wasn’t one of them. MarketBeat thinks these five companies may be even better buys.